Abogen Biosciences Advances into Clinical Trials with Lyophilized mRNA Vaccines ABO1105 (RSV) and ABO1108 (VZV)

May 16, 2025 18:02 CST Updated 18:02

Abogen

Nucleic Acid Drug Developer

Innovation Empowers Acceleration of Clinical Translation

Abogen Biosciences, with 19 new patent families in core technology areas such as base modification and LNP delivery, ranks prominently in the global mRNA patent applications for 2024.Ranked Fourth，Highlights the strength of China in the global mRNA industry landscapeRise(See "Related Reading" at the end of the article).

Empowered by innovative patent technologies with high efficiency and quality, two new types of mRNA vaccines independently developed——Lyophilized Respiratory Syncytial Virus (RSV) Vaccine(Code: ABO1105) andLyophilized Varicella-Zoster Virus (VZV) Vaccine(Code: ABO1108) officially entered the clinical research phase with the successive launch of Phase I clinical trials in Guangxi, China, on May 15-16, 2025.

On the 15th, the ABO1105 clinical trial kick-off meeting was held at the Disease Prevention and Control Center in Baise City, Guangxi.The meeting was hosted by Huang Teng, Deputy Director and Associate Chief Physician of the Vaccine Clinical Research Institute of the Autonomous Region Center for Disease Control and Prevention; Dr. Ying Bo, Founder, Chairman and Chief Executive Officer of Abogen Biosciences.Deliver a speech for the launch ceremony;Baise CDC Director Yushuilan warmly welcomed the leaders and experts attending the meeting; Mo Zhaojun, General Manager of Shanghai StemMed Pharmaceutical Development Co., Ltd., delivered a speech on behalf of the monitoring party.

ABO1105 Clinical Trial Kick-off Meeting Group Photo

Launch Ceremony

Subsequently, Deputy Director Huang Teng, Abogen's Chief Medical Officer Song Wenjie, Director and Chief Physician Han Yanbin of the Autonomous Region Center for Disease Control, Principal Investigator Shi Liwei, and Quality Control Team Member Feng Zhengli each delivered thematic lectures. They provided a detailed introduction to the principles of quality management in vaccine clinical research, the development process of the trial vaccine, implementation requirements of the trial protocol, and quality control, among other specific content. They also analyzed issues encountered in previous vaccine clinical trials across different regions, summarized experiences, and offered valuable insights for the implementation of clinical trials.

Theme Training Site

On the 16th,The kick-off meeting for the ABO1108 clinical trial was held in Rongshui, Guangxi. The meeting was hosted byHuang Teng, Deputy Director of the Vaccine Department at the Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, and Principal Investigator of the VZV clinical study, presided over; Dr. Ying Bo, Founder, Chairman, and Chief Executive Officer of Abogen BiosciencesDelivered a speech at the launch ceremony; Feng Jiping, Director of the Disease Control and Prevention Bureau of Rongshui Miao Autonomous County, Wei Pengchong, Chairman of Beijing Simuric Pharmaceutical Technology Co., Ltd., and other guests attended and delivered speeches.

ABO1108 Clinical Trial Kick-off Meeting Group Photo

Launch Ceremony and Training Session

Innovation Builds Foundation, Creating Full-Chain Advantages

Abogen has long been deeply engaged in scientific research, independently developing several key technologies that cover various aspects such as mRNA design and modification, LNP delivery, innovative formulation development, and large-scale production, spanning the entire mRNA pharmaceutical process.

The Phase I clinical trials launched this time for ABO1105 and ABO1108 both adoptedAbogen's proprietary base modification technology capable of breaking through Nobel Prize-level patents, andProprietary Lipid Nanoparticle (LNP) Delivery System, the core components of the system areThe only ionizable lipid in China that has undergone large-scale Phase III clinical validation and possesses independent intellectual property rights, which has currently obtained patent authorization in multiple major countries including China, the United States, Australia, and Europe.

Both also adoptedAbogen's Mature Freeze-Dried Formulation Process, which can be stably stored at 2-8℃.More than 2 years, with goodStability, storage convenience, and accessibility`, is expected to provide a safer and more effective vaccine solution for the prevention of RSV and VZV infections.`

In addition, the two rely onAbogen's proprietary protein structure and RNA sequence design platform, throughOptimization of Protein Structure through Mutation Site Combinations, through codon optimization and UTR screening, the immunogenicity and drugability of the mRNA sequence are enhanced, and the product has independent intellectual property rights.

The full-chain development of ABO1105 and ABO1108, along with their efficient and rapid clinical initiation, fully demonstrates Abogen's strong capability to swiftly transform cutting-edge patented technologies into vaccine research and clinical applications.

In the future, Abogen will continue to strengthen its technical foundation, promote the transformation of innovative achievements, and provide high-quality "Chinese solutions" for global public health and public health challenges.

Breakthrough Nobel Prize-Level Base Modification Technology: Abogen's Lyophilized mRNA Vaccine Approved for Clinical Trials

Will mRNA Have Its Second Spring in 2025?

KnowMade Original Summary and Link:

"Sanofi, Abogen, and Pfizer:

Rising Stars in the Top Five"

"Sanofi, Abogen, and Pfizer have emerged as key players in 2024, making notable strides within the top five...

Abogen also advanced to fourth position in 2024 with 13 new patent families, highlighting its growing prominence in biotechnology. Known for its expertise in mRNA technology, Abogen has quickly established itself as a significant player since its founding in 2019, particularly in developing cationic lipids for lipid nanoparticle (LNP) systems. Due to its youthful yet extensive portfolio, strong emphasis on lipidic components, and innovation in therapeutic areas, the company is a dynamic force in the evolving field of mRNA delivery."

https://www.knowmade.com/technology-news/life-sciences-news/healthcare-technology-news/patenting-activity-in-2024-an-insightful-analysis/

About Us

Abogen Biosciences (referred to as "Abogen") is an innovative biopharmaceutical company focused on the research and development of messenger ribonucleic acid (mRNA) drugs. The company owns industry-leading, proprietary intellectual property rights in mRNA and nanodelivery technology platforms. It is one of the few mRNA drug R&D enterprises in China with complete value chain capabilities, covering all aspects from mRNA design, formulation development to large-scale production. The company has established a rich product pipeline, spanning multiple fields including infectious disease prevention and control (such as mRNA COVID-19 vaccines), cancer immunotherapy, and protein replacement therapy.